MétaCan
Menu
Back to cohort
Record W4390506313 · doi:10.1080/14656566.2023.2298340

The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis

2024· review· en· W4390506313 on OpenAlexaff
Nicholas Kleine, Kayla M. Teopiz, Joshua D. Di Vincenzo, Roger Ho, Stephanie L. Galibert, Amrita Samra, Samuel P.M. Zilm, H. Rebekah, Giacomo d’Andrea, Hartej Gill, Felicia Ceban, Shakila Meshkat, Sabrina Wong, Gia Han Le, Angela T.H. Kwan, Joshua D. Rosenblat, Taeho Greg Rhee, Rodrigo B. Mansur, Roger S. McIntyre

Bibliographic record

VenueExpert Opinion on Pharmacotherapy · 2024
Typereview
Languageen
FieldMedicine
TopicMaternal Mental Health During Pregnancy and Postpartum
Canadian institutionsMcMaster UniversityUniversity of TorontoToronto Western HospitalBrain and Cognition Discovery FoundationUniversity Health Network
Fundersnot available
KeywordsMedicineNeuroactive steroidMajor depressive disorderAntidepressantPostpartum depressionDepression (economics)PsychiatryPremenstrual dysphoric disorderVortioxetineChildbirthNumber needed to treatMental healthPregnancyGABAA receptorInternal medicineMoodAnxietyReceptorRelative riskMenstrual cycle

Abstract

fetched live from OpenAlex

Introduction Major depressive disorder (MDD) is a common and debilitating mental illness. Postpartum depression (PPD) impacts women globally and is one of the most common complications of childbirth that is underdiagnosed and undertreated, adversely impacting the mental health of women, children, and partners.Available antidepressant medications require weeks to months before showing effect. In this setting, zuranolone, an oral neuroactive steroid and a positive allosteric modulator of GABAA receptors, is an attractive alternative as a rapid-acting antidepressant treatment.Areas covered This article reviews zuranolone (SAGE217), focusing on available clinical studies in individuals with PPD and MDD. This paper adds to the extant literature by presenting the efficacy data as Number Needed to Treat (NNT) to facilitate indirect comparisons with other antidepressants.Expert opinion Zuranolone is a novel rapid-acting (i.e. two week course) oral antidepressant for the treatment of adults with PPD with ongoing clinical trials evaluating its efficacy in adults with MDD. Zuranolone is well tolerated with no significant safety concerns in any clinical trials completed to date. Zuranolone will be scheduled by the Drug Enforcement Agency (DEA).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.011
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.010
Threshold uncertainty score0.034

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.011
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0070.008
Bibliometrics0.0030.003
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0100.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.046
GPT teacher head0.445
Teacher spread0.398 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueExpert Opinion on PharmacotherapySame topicMaternal Mental Health During Pregnancy and PostpartumFrench-language works237,207